Anika Therapeutics Announces Date for Third Quarter Results and Conference Call.

Business Editors

WOBURN, Mass.--(BUSINESS WIRE)--Oct. 29, 2001

Anika Therapeutics, Inc. (Nasdaq:ANIK) today said it plans to issue third quarter results before the opening of the market on November 1, 2001.

The company plans to hold a conference call that same day at 11:00 a.m. EST to discuss quarterly financial results, business highlights and outlook. In addition, the company may answer one or more questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.

To listen to the conference call, dial 416/620-2415 approximately 10 minutes before the starting time and reference Anika Therapeutics. A playback of the call will be available from 1:00 p.m. EST Thursday, November 1, through 1:00 p.m. EST Tuesday, November 6. To listen to the recorded call, dial 800/633-8284, access code 19937478.

About Anika Therapeutics

Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb. STAARVICS(TM)-II, an injectable ophthalmic viscoelastic is produced for STAAR Surgical Company.

The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties and other factors. The words "believe," "will," "may," "would," "expect," "anticipate," "intend," "estimate" and other expressions which are predictions of or indicate future events and trends and which do not relate to historical matters identify forward-looking statements. The company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors, which include the results of its research and development efforts and timing of regulatory approval. There is a risk that: (i) the clinical data will not support the efficacy of ORTHOVISC(R), (ii) the company will not be able to successfully complete the Phase III clinical trial of ORTHOVISC(R) or (iii) the clinical trial will not support a PMA application and/or FDA approval in a timely manner or at all. In addition, there can be no assurance that any delay in receiving any such approvals will not adversely affect the company's competitive position. Certain other factors that might cause the company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors and Certain Factors Affecting Future Operating Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the year ended December 31, 2000, the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2001, and the company's other filings with the Securities and Exchange Commission, and the company's other press releases.